Spravato Logo.png

A New Day Begins With Spravato

Clouds in Sky

FDA Approved

IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT (AD) FOR TREATMENT-RESISTANT DEPRESSION (TRD) IN ADULTS¹

The first and only NMDA receptor antagonist approved for TRD in adults

SPRAVATO™ hypothesized mechanism of action

NasalSpray_Effects.png

Reach Your Treatment Goals Today

BASELINE PSYCHIATRIC PATIENT CHARACTERISTICS

Spravato_Comparison.png
Studied in more than 1700 adult patients with treatment-resistant depression

BASELINE PSYCHIATRIC PATIENT CHARACTERISTICS

1  2

Spravato_BaselinePsychiatric.png

References:

1.SPRAVATO™ [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. March 2019.

2.Data on file. Janssen Pharmaceuticals, Inc. Titusville, NJ.

Indication:
SPRAVATO™ (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant (AD), for the treatment of treatment-resistant depression (TRD) in adults.​

SPRAVATO™ is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO™ as an anesthetic agent have not been established.

For more information on SPRAVATO treatment, call our mental health clinic at 855.4CHARAK

Use The Link Below To Learn More About Important Safety Information

Get In Touch! We Are Here For You